ClinicalTrials.gg
CompletedNCT03636061Updated Oct 25, 2021Results posted

Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

A Phase 2 interventional study of OC-01 (varenicline) nasal spray and Placebo (vehicle) nasal spray in Dry Eye Disease, sponsored by Oyster Point Pharma, Inc.. Completed at 3 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2021-10-25.

Sponsored by Oyster Point Pharma, Inc. (part of Viatris Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing varenicline in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. Varenicline · Dry Eye Syndromes.

Enrollment
3rd of 13
182 · median 60
Started
2018
with 1 other
Phase 2
3 of 13
none open now
Registered
1st of 13
by date
Lead sponsor
4 of 13
Oyster Point Pharma, Inc.

Among the 13 studies testing varenicline in Dry Eye Syndromes, this one is the 3rd largest by enrollment, is one of 2 that started in 2018, is one of 3 in phase 2, and was the 1st registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

2 of the 13 studies testing varenicline in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing varenicline in Dry Eye Syndromes, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease

Read the detailed description

This was a Phase 2b, multicenter, randomized, double-masked, placebo controlled study designed to evaluate the safety and efficacy of OC 01 nasal spray in adult subjects with DED. The study randomized 182 subjects, at least 22 years of age, who had a physician's diagnosis of dry eye disease and met all other study eligibility criteria to receive an application of OC-01 or placebo twice daily (BID) for 4 weeks.

03

Conditions studied

  • Dry Eye Disease

Browse trials for

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have used and/or desired to use an artificial tear substitute for dry eye symptoms within 6 months prior to Visit 1

Exclusion criteria

Exclusion Criteria:

  • Have had any intraocular surgery (such as cataract surgery), extraocular surgery (such as blepharoplasty) in either eye within three months or refractive surgery within twelve months of Visit 1
  • Have a history or presence of any ocular disorder or condition in either eye that would, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety such as significant corneal or conjunctival scarring; pterygium or nodular pinguecula; current ocular infection, conjunctivitis, or inflammation not associated with dry eye; anterior (epithelial) basement membrane corneal dystrophy or other corneal dystrophy or degeneration; ocular herpetic infection; evidence of keratoconus; etc. Blepharitis not requiring treatment and mild meibomian gland disease that are typically associated with DED are allowed.
  • Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study or with the lengthier assessments required by the study (e.g., current systemic infection, uncontrolled disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.)
  • Have a known to any of the procedural agents or study drug components
  • Have any condition or history that, in the opinion of the investigator, may interfere with study compliance, outcome measures, safety parameters, and/or the general medical condition of the subject
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
182 participants (actual)

Study arms

  • Active comparator
    OC-01 Low Dose, 0.12 mg/mL

    OC-01 (varenicline) nasal spray, Low Dose, 0.12 mg/mL

    Drug: OC-01 (varenicline) nasal spray

  • Active comparator
    OC-01 Mid Dose, 0.6 mg/mL

    OC-01 (varenicline) nasal spray Mid dose, 0.6 mg/mL

    Drug: OC-01 (varenicline) nasal spray

  • Active comparator
    OC-01 High Dose, 1.2 mg/mL

    OC-01 (varenicline) nasal spray High dose, 1.2 mg/mL

    Drug: OC-01 (varenicline) nasal spray

  • Placebo comparator
    Placebo

    Placebo (vehicle) nasal spray

    Drug: Placebo (vehicle) nasal spray

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change in Schirmer's Test Score From Baseline to 28 Days

    The primary end point was the change in anesthetized Schirmer's Test Score (STS) from baseline to 28 days in the study eye following treatment with OC-01. Schirmer's test score from 0-35 mm where a higher score is indicative of a better outcome.

    Time frame: 28 Days [Visit 1 (baseline) and Visit 5 (28 days)]

Secondary outcomes

  1. Change From Baseline in Eye Dryness Score From Baseline to Day 28

    Change in Eye Dryness Score from baseline to 28 days. Eye Dryness (EDS) on a Visual Analogue Scale (VAS) from 0 (no discomfort) to 100 (maximum discomfort) millimeters where a lower score is indicative of a better outcome.

    Time frame: 28 days [Visit 1 (baseline and Visit 5 (28 days)]

  2. Change From Baseline to Day 21 in Eye Dryness Score at 5 Minutes Post Treatment in the CAE.

    Change from baseline to Day 21 in Eye Dryness Score at 5 minutes post treatment in the CAE. Eye Dryness (EDS) on a Visual Analogue Scale (VAS) from 0 (no discomfort) to 100 (maximum discomfort) millimeters where a lower score is indicative of a better outcome.

    Time frame: 21 days [Visit 1 (baseline) and Visit 4 (21 days)]

07

Results

Posted Oct 25, 2021

Participant flow

Participant flow — Overall Study
MilestoneOC-01 Low Dose, 0.12 mg/mlOC-01 Mid Dose, 0.6 mg/mlOC-01 High Dose, 1.2 mg/mlPlacebo
Started47484443
Completed47464043
Not completed0240

Outcome measures

PrimaryMean Change in Schirmer's Test Score From Baseline to 28 Days

The primary end point was the change in anesthetized Schirmer's Test Score (STS) from baseline to 28 days in the study eye following treatment with OC-01. Schirmer's test score from 0-35 mm where a higher score is indicative of a better outcome.

Time frame:
28 Days [Visit 1 (baseline) and Visit 5 (28 days)]
Reported as:
Least squares mean · score on a scale, mm
Mean Change in Schirmer's Test Score From Baseline to 28 Days
score on a scale, mmOC-01 Low Dose, 0.12 mg/mLOC-01 Mid Dose, 0.6 mg/MLOC-01 High Dose, 1.2 mg/mLPlacebo
Mean Change in Schirmer's Test Score From Baseline to 28 Days10.1 ± 1.2611.7 ± 1.2711.0 ± 1.393.2 ± 1.31
SecondaryChange From Baseline in Eye Dryness Score From Baseline to Day 28

Change in Eye Dryness Score from baseline to 28 days. Eye Dryness (EDS) on a Visual Analogue Scale (VAS) from 0 (no discomfort) to 100 (maximum discomfort) millimeters where a lower score is indicative of a better outcome.

Time frame:
28 days [Visit 1 (baseline and Visit 5 (28 days)]
Reported as:
Least squares mean · score on a scale, mm
Change From Baseline in Eye Dryness Score From Baseline to Day 28
score on a scale, mmOC-01 Low Dose, 0.12 mg/mlOC-01 Mid Dose, 0.6 mg/mlOC-01 High Dose, 1.2 mg/mlPlacebo
Change From Baseline in Eye Dryness Score From Baseline to Day 28-11.6 ± 3.63-18.9 ± 3.67-15.6 ± 4.02-5.4 ± 3.8
SecondaryChange From Baseline to Day 21 in Eye Dryness Score at 5 Minutes Post Treatment in the CAE.

Change from baseline to Day 21 in Eye Dryness Score at 5 minutes post treatment in the CAE. Eye Dryness (EDS) on a Visual Analogue Scale (VAS) from 0 (no discomfort) to 100 (maximum discomfort) millimeters where a lower score is indicative of a better outcome.

Time frame:
21 days [Visit 1 (baseline) and Visit 4 (21 days)]
Reported as:
Least squares mean · score on a scale, mm
Change From Baseline to Day 21 in Eye Dryness Score at 5 Minutes Post Treatment in the CAE.
score on a scale, mmOC-01 Low Dose, 0.12 mg/mlOC-01 Mid Dose, 0.6 mg/mlOC-01 High Dose, 1.2 mg/mlPlacebo
Change From Baseline to Day 21 in Eye Dryness Score at 5 Minutes Post Treatment in the CAE.-8.1 ± 2.7-16.0 ± 2.7-18.4 ± 3.0-4.4 ± 2.8

Adverse events

Collected over Adverse Events were collected from the first dose of study drug administration until the final study visit at Visit 5 (28 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OC-01 Low Dose, 0.12 mg/mL0/47 (0%)0/47 (0%)33/47 (70.2%)
OC-01 Mid Dose, 0.6 mg/mL0/48 (0%)1/48 (2.1%)44/48 (91.7%)
OC-01 High Dose, 1.2 mg/mL0/44 (0%)0/44 (0%)41/44 (93.2%)
Placebo0/43 (0%)0/43 (0%)11/43 (25.6%)
Most frequent serious events
Most frequent serious events
EventOC-01 Low Dose, 0.12 mg/mLOC-01 Mid Dose, 0.6 mg/mLOC-01 High Dose, 1.2 mg/mLPlacebo
AnaemiaBlood and lymphatic system disorders0/471/480/440/43
Most frequent other events
Showing 10 of 15
Most frequent other events
EventOC-01 Low Dose, 0.12 mg/mLOC-01 Mid Dose, 0.6 mg/mLOC-01 High Dose, 1.2 mg/mLPlacebo
SneezingRespiratory, thoracic and mediastinal disorders29/4738/4837/440/43
CoughRespiratory, thoracic and mediastinal disorders4/476/4811/440/43
Throat irritationRespiratory, thoracic and mediastinal disorders0/477/489/440/43
Instillation site irritationGeneral disorders3/478/488/440/43
Ocular TEAEsEye disorders1/472/481/447/43
Dysaesthesia pharynxRespiratory, thoracic and mediastinal disorders5/474/483/440/43
Visual acuity reducedEye disorders1/471/480/443/43
Nasal drynessRespiratory, thoracic and mediastinal disorders1/470/480/442/43
HeadacheNervous system disorders0/470/482/441/43
BlepharospasmEye disorders0/470/480/441/43

Baseline characteristics

Age, Continuous
Age, Continuous(years)OC-01 Low Dose, 0.12 mg/mLOC-01 Mid Dose, 0.6 mg/mLOC-01 High Dose, 1.2 mg/mLPlaceboTotal
Mean64.2 ± 12.766.5 ± 9.467.4 ± 10.664 ± 10.365.5 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)OC-01 Low Dose, 0.12 mg/mLOC-01 Mid Dose, 0.6 mg/mLOC-01 High Dose, 1.2 mg/mLPlaceboTotal
Female36343532137
Male111491145
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OC-01 Low Dose, 0.12 mg/mLOC-01 Mid Dose, 0.6 mg/mLOC-01 High Dose, 1.2 mg/mLPlaceboTotal
Hispanic or Latino832518
Not Hispanic or Latino39454238164
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OC-01 Low Dose, 0.12 mg/mLOC-01 Mid Dose, 0.6 mg/mLOC-01 High Dose, 1.2 mg/mLPlaceboTotal
American Indian or Alaska Native01102
Asian34018
Native Hawaiian or Other Pacific Islander00101
Black or African American246214
White42393640157
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)OC-01 Low Dose, 0.12 mg/mLOC-01 Mid Dose, 0.6 mg/mLOC-01 High Dose, 1.2 mg/mLPlaceboTotal
United States47484443182
Schirmer's Test Score
Schirmer's Test Score(mm)OC-01 Low Dose, 0.12 mg/mLOC-01 Mid Dose, 0.6 mg/mLOC-01 High Dose, 1.2 mg/mLPlaceboTotal
Mean5.2 ± 3.14.8 ± 2.75.5 ± 3.04.5 ± 2.95.0 ± 2.9
08

Study locations

3 sites
  • Newport Beach
    Newport Beach, California 92663, United States
  • Indianapolis
    Indianapolis, Indiana 46290, United States
  • Andover
    Andover, Massachusetts 01810, United States
09

References and documents

Publications

  • Nijm LM, Zhu D, Hemphill M, Blemker GL, Hendrix LH, Kabat AG, Gibson AA. Does Menopausal Status Affect Dry Eye Disease Treatment Outcomes with OC-01 (Varenicline Solution) Nasal Spray? A Post Hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials. Ophthalmol Ther. 2023 Feb;12(1):355-364. doi: 10.1007/s40123-022-00607-7. Epub 2022 Nov 18. PubMed 36401081 ↗
  • Wirta D, Torkildsen GL, Boehmer B, Hollander DA, Bendert E, Zeng L, Ackermann M, Nau J. ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease. Cornea. 2022 Oct 1;41(10):1207-1216. doi: 10.1097/ICO.0000000000002941. Epub 2021 Dec 21. PubMed 36107843 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Sep 2018, 1 month.

Results were first posted in Oct 2021, 3 years after primary completion. A results delay was requested in May 2019.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 1 month is below that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2018
First posted
Aug 17, 2018
StartActual
Aug 15, 2018
Primary completionActual
Sep 26, 2018
CompletionActual
Sep 26, 2018
Results delay requested
May 14, 2019
Results first posted
Oct 25, 2021
Last update
Oct 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03636061
Responsible party
Sponsor
First posted
Aug 17, 2018
Start date
Aug 15, 2018
Primary completion
Sep 26, 2018
Completion
Sep 26, 2018
Results posted
Oct 25, 2021
Last update
Oct 25, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion